News | BTG Specialty Pharmaceuticals

Date

Title

01 Dec 2021

First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
30 Nov 2021

SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
21 Oct 2021

Ben Watt Joins SERB and BTG as Group CFO
27 Sep 2021

BTG Specialty Pharmaceuticals advances global regulatory program for glucarpidase, sold as Voraxaze® in the US

BTG Specialty Pharmaceuticals partner Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase in Japan
21 Apr 2021

BTG Specialty Pharmaceuticals Calls on Consumers and Retailers to Consider the Facts About Venom Extractors

Firm publishes summary of evidence showing lack of efficacy and risks
01 Mar 2021

SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines

Acquisition gives SERB a commercial presence in the US and expands critical care portfolio